Piloting the development of a cost-effective evidence-informed clinical pathway: Managing hypertension in Jordanian primary care

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 2, 2011, Pages 151-158

  Chalkidou, Kalipso ^a   Lord, Joanne ^b   Obeidat, Nour A ^c   Alabbadi, Ibriham A ^d   Stanley, Adrian G ^e,f   Bader, Rania ^f,g   Momani, Aiman ^h   O'Mahony, Rachel M ⁱ   Qatami, Lara ^j   Cutler, Derek ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c King Hussein Institute for Biotechnology and Cancer   (Jordan)

^d UNIVERSITY OF JORDAN   (Jordan)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^g King Abdullah II Bin A1 Hussein Street ^*  (Jordan)

^h PharmaNet   (Jordan)

ⁱ ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^j KING HUSSEIN CANCER CENTER   (Jordan)

more..

Author keywords

Evidence based medicine; Hypertension; Jordan; LMIC; NICE; Treatment guidelines

Indexed keywords

EVIDENCE-BASED MEDICINE; HYPERTENSION; JORDAN; LMIC; NICE; TREATMENT GUIDELINES;

COST EFFECTIVENESS; COSTS; DECISION MAKING; HEALTH CARE; MATHEMATICAL MODELS; MEDICAL PROBLEMS;

COST BENEFIT ANALYSIS;

ALGORITHM; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; JORDAN; MODEL; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL PATHWAY; COST BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT SYSTEM; DEVELOPING COUNTRY; ECONOMICS; EDUCATION; EDUCATIONAL MODEL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; INFORMATION PROCESSING; INSURANCE; PILOT STUDY; PRIMARY HEALTH CARE; PROGRAM DEVELOPMENT; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; CRITICAL PATHWAYS; DECISION MAKING; DECISION SUPPORT SYSTEMS, CLINICAL; DEVELOPING COUNTRIES; EDUCATION; EVIDENCE-BASED MEDICINE; FOCUS GROUPS; GREAT BRITAIN; HUMANS; HYPERTENSION; INSURANCE COVERAGE; JORDAN; MODELS, EDUCATIONAL; PILOT PROJECTS; PRIMARY HEALTH CARE; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; QUALITY OF LIFE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 79961121257     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462311000122     Document Type: Article

References (24)

1. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: Prevalence and associated risk factors. J Intern Med. 1998;244:317-323.
2. Al-Azzam SI, Najjar RB, Khadar YS. Awareness of physicians in Jordan about the treatment of high blood pressure according to the seventh report of the Joint National Committee (JNC VII). Eur J Cardiovasc Nurs. 2007;6:223-232.
3. Chalkidou K, Levine R, Dillon A. Helping poorer countries make locally informed health decisions. Br Med J. 2010 341:284-286.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
5. ESH/ESC Hypertension guidelines committee. Practice guidelines for primary care physicians. 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003;21:1779-1786.
6. High Health Council Jordan. http://www.hhc.gov. jo/HHC/index-e.html (accessed October 18, 2010).
7. International Society for Pharmoeconomics and Outcomes Research. Principles of good practice for decision analytic modeling. http://www.ispor. org/workpaper/research-practices/ PrinciplesofGoodPracticeforDecisionAnalyticModeling-ModelingStudies.pdf.
8. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med. 2008;359:2417-2428.
9. Joint Procurement Department Jordan. http://images.jordan. gov. jo/wps/wcm/connect/gov/egov/government+ministries+-+entities/ joint+procurement+department/general+information/ joint+procurement+department+general+information.
10. Jordan Breast Cancer Program. http://www.jbcp. jo/en.
11. Jordan Directorate of Disease Control & Prevention. Survey of prevalence of selected risk factors for chronic disease. Amman, Jordan: Directorate of Disease Control & Prevention; 2007.
12. Jordan Food and Drug Administration website. http://www.jfda.jo/EN/Laws/ LawInfo.aspx?id=507.
13. Jordan MeTA Council. Medicines transparency alliance national workplan: Jordan. Amman, Jordan: Jordan MeTA Council; 2008.
14. Lavis JN, Panisset U. EVIPNet Africa's first series of policy briefs to support evidence-informed policymaking. Int J Technol Assess Health Care. 2010;26:229-232.
15. Marquez P, Chalkidou K, Cutler D, et al. Putting evidence into practice to redesign healthcare: Some lessons for Europe and Central Asia from the United Kingdom. World Bank Knowledge Brief. Washington, DC: World Bank; 2010.
16. Medicine Transparency Alliance website. http://www.medicinestransparency. org/.
17. MeTA Jordan. A model Standard Treatment Guideline (STG) for Essential Hypertension and Improving Rational Use of Medicines in Jordan. http://www.medicinestransparency.org/fileadmin/uploads/Documents/Global-Forum/ Global-Forum-case-studies/MeTA-Jordan-Standard-Treatment-Guidelines.pdf.
18. National Collaborating Centre for Chronic Conditions. Hypertension: Management in adults in primary care: Pharmacological update. London: Royal College of Physicians; 2006.
19. Oxman A and Hanney S. SUPPORT Tools for evidenceinformed health Policymaking (STP). http://www.health-policy-systems.com/supplements/7/S1
20. Rational Drug Use Unit, Jordan Food and Drug Administration website. http://www.jfda.jo/RDU/en-US/IndexPage.aspx (accessed October 18, 2010).
21. Venkat Narayan KM, Ali M, Koplan JP. Global Noncommunicable Diseases - Where Worlds Meet. N Engl J Med. 2010;363:1196-1198.
22. Wiysonge CSU, Bradley HA, Mayosi BM, et al. Betablockers for hypertension Cochrane Database Syst Rev. 2010;1:CD002003.
23. World Bank HNPStats. Health, nutrition and population statistics. http://ddp-ext.worldbank.org/ext/ddpreports/ViewSharedReport?&CF= 1&REPORT-ID=10309&REQUEST-TYPE=VIEWADVANCED&HF=N.
24. Yusuf F, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.